Dupixent is the first and only biologic ... Phase 3), pediatric atopic dermatitis (6 months to 5 years of age, Phase 2/3), eosinophilic esophagitis (Phase 3), chronic obstructive pulmonary disease ...

Dupixent (dupilumab) was the first biologic treatment approved for atopic dermatitis. It became available in 2017. It is currently approved for adults and adolescents 6 months and older with ...

Sanofi and Regeneron’s Dupixent has already transformed the treatment of moderate-to-severe atopic dermatitis since it was first approved in 2017 – but it seems the IL-4 and IL-13 inhibitor ...

Dupixent is a brand-name injection that doctors prescribe to treat certain conditions, including atopic dermatitis and asthma. Injection site reactions, such as pain, are common side effects of ...

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis ... In children 6 months to less than 12 years ...

Table 4. Relative risks for atopic dermatitis (AD) or cow's milk protein allergy (CMPA) at the age of 6 months based on the presences or not of early life infection, in the total sample and by study ...

Over the next 10 years, GlobalData has predicted that Dupixent will remain the most prescribed biologic therapy for atopic dermatitis, with global sales of $5.3 billion in 2027.

The indications for this candidate are also endless and some examples of disorders it could go after are: Atopic Dermatitis [AD ... for TH2 inflammation like Dupixent [Dupilumab] from Sanofi ...

Dupixent is now approved in several countries, including the United States and EU, for six type II inflammatory diseases, namely severe chronic rhinosinusitis with nasal polyposis, severe asthma, ...